Cost-effectiveness of rimegepant oral lyophilisate compared to best supportive care for the acute treatment of migraine in the UK

被引：0
|
作者：
Johnston, K. [1 ]
Powell, L. [1 ]
Popoff, E. [1 ]
L'Italien, G. [2 ]
Pawinski, R. [3 ]
Ahern, A. [3 ]
Large, S. [3 ]
Tran, T. [4 ]
Jenkins, A. [3 ]
机构：
[1] Broadst Hlth Econ & Outcomes Res, Vancouver, BC, Canada
[2] Biohaven Pharmaceut Inc, New Haven, CT USA
[3] Pfizer Ltd, Tadworth, England
[4] Pfizer Canada, Kirkland, PQ, Canada
来源：
JOURNAL OF HEADACHE AND PAIN | 2024年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P038
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Cost-effectiveness of rimegepant oral lyophilisate compared to best supportive care for the acute treatment of migraine in the UK
    Johnston, Karissa
    Powell, Lauren C.
    Popoff, Evan
    L'Italien, Gil J.
    Pawinski, Robert
    Ahern, Aideen
    Large, Sam
    Tran, Thang
    Jenkins, Aaron
    JOURNAL OF MEDICAL ECONOMICS, 2024, 27 (01) : 627 - 643
  • [2] Cost-effectiveness analysis of rimegepant for on-demand acute treatment of migraine in China
    Tian, Shuo
    Yang, Yuping
    Tan, Shenglan
    Luo, Jiani
    Yang, Chuanyu
    Liu, Qiao
    Guo, Yujin
    FRONTIERS IN NEUROLOGY, 2024, 15
  • [3] Cost-effectiveness of abobotulinumtoxinA plus best supportive care compared with best supportive care alone for early treatment of adult lower limb spasticity following an acute event
    Moore, Peter
    Danchenko, Natalya
    Weidlich, Diana
    Tijerina, Alejandra Rodarte
    PLOS ONE, 2024, 19 (02):
  • [4] LONG-TERM COST-EFFECTIVENESS OF LASMIDITAN, UBROGEPANT AND RIMEGEPANT FOR TREATMENT OF ACUTE MIGRAINE
    Touchette, D.
    Atlas, S. J.
    Agboola, F. O.
    Joshi, M.
    Lee, T. A.
    Chapman, R. H.
    Pearson, S. D.
    Rind, D. M.
    VALUE IN HEALTH, 2020, 23 : S261 - S261
  • [5] COST-EFFECTIVENESS ANALYSIS OF TREATMENT WITH ABOBOTULINUMTOXINA COMPARED TO BEST SUPPORTIVE CARE IN PATIENTS WITH UPPER LIMB SPASTICITY IN SWEDEN
    Forsmark, A.
    Danchenko, N.
    Ertzgaard, P.
    Lundkvist, J.
    Rosengren, L.
    VALUE IN HEALTH, 2018, 21 : S338 - S339
  • [6] COST-EFFECTIVENESS OF ORAL TOPOTECAN PLUS BEST SUPPORTIVE CARE VERSUS BEST SUPPORTIVE CARE ALONE IN PATIENTS WITH RELAPSED SMALL-CELL LUNG CANCER (SCLC) IN THE UK
    Lykopoulos, K.
    Morris, S.
    Papo, N.
    O'Brien, M. E.
    VALUE IN HEALTH, 2008, 11 (06) : A482 - A482
  • [7] COST-EFFECTIVENESS OF ORAL TRIPTANS FOR ACUTE MIGRAINE: MIXED TREATMENT COMPARISON
    Asseburg, Christian
    Peura, Piia
    Oksanen, Tuija
    Turunen, Juha
    Purmonen, Timo
    Martikainen, Janne
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2012, 28 (04) : 382 - 389
  • [8] Cost-effectiveness of oral topotecan plus best supportive care versus best supportive care alone in patients with relapsed small-cell lung cancer (SCLC) in the UK
    O'Brien, Mary E.
    Morris, Stephen
    Papo, Natalie L.
    Lykopoulos, Konstantinos
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S818 - S818
  • [9] COST-EFFECTIVENESS OF DIFELIKEFALIN COMPARED TO BEST SUPPORTIVE CARE FOR TREATMENT OF CHRONIC KIDNEY DISEASE-ASSOCIATED PRURITUS IN AUSTRALIA
    Jackson, D.
    Ratkovic, M.
    Tilden, D.
    Soro, M.
    Schaufler, T.
    Grava, A.
    Harsley, S.
    Brydon, S.
    VALUE IN HEALTH, 2024, 27 (12) : S179 - S179
  • [10] COST-EFFECTIVENESS ANALYSIS OF A DIGITAL HEALTH APPLICATION (DIGA) PLUS BEST SUPPORTIVE CARE (BSC) COMPARED TO BSC IN GERMAN EPISODIC MIGRAINE PATIENTS
    Walter, E.
    Wegner, S.
    Burziwoda, D.
    VALUE IN HEALTH, 2022, 25 (12) : S129 - S129
12345